These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27429025)

  • 1. A Novel Prognostic Index in Patients With Hepatocellular Cancer Waiting for Liver Transplantation: Time-Radiological-response-Alpha-fetoprotein-INflammation (TRAIN) Score.
    Lai Q; Nicolini D; Inostroza Nunez M; Iesari S; Goffette P; Agostini A; Giovagnoni A; Vivarelli M; Lerut J
    Ann Surg; 2016 Nov; 264(5):787-796. PubMed ID: 27429025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delta-slope of alpha-fetoprotein improves the ability to select liver transplant patients with hepatocellular cancer.
    Lai Q; Inostroza M; Rico Juri JM; Goffette P; Lerut J
    HPB (Oxford); 2015 Dec; 17(12):1085-95. PubMed ID: 26373980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
    Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
    J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation.
    Toso C; Meeberg G; Hernandez-Alejandro R; Dufour JF; Marotta P; Majno P; Kneteman NM
    Hepatology; 2015 Jul; 62(1):158-65. PubMed ID: 25777590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation.
    Lai Q; Avolio AW; Graziadei I; Otto G; Rossi M; Tisone G; Goffette P; Vogel W; Pitton MB; Lerut J;
    Liver Transpl; 2013 Oct; 19(10):1108-18. PubMed ID: 23873764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reframing the approach to patients with hepatocellular carcinoma: Longitudinal assessment with hazard associated with liver transplantation for HCC (HALTHCC) improves ablate and wait strategy.
    Firl DJ; Kimura S; McVey J; Hashimoto K; Yeh H; Miller CM; Markmann JF; Sasaki K; Aucejo FN
    Hepatology; 2018 Oct; 68(4):1448-1458. PubMed ID: 29604231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria.
    Duvoux C; Roudot-Thoraval F; Decaens T; Pessione F; Badran H; Piardi T; Francoz C; Compagnon P; Vanlemmens C; Dumortier J; Dharancy S; Gugenheim J; Bernard PH; Adam R; Radenne S; Muscari F; Conti F; Hardwigsen J; Pageaux GP; Chazouillères O; Salame E; Hilleret MN; Lebray P; Abergel A; Debette-Gratien M; Kluger MD; Mallat A; Azoulay D; Cherqui D;
    Gastroenterology; 2012 Oct; 143(4):986-94.e3; quiz e14-5. PubMed ID: 22750200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of biological and morphological parameters for the selection of patients with hepatocellular carcinoma waiting for liver transplantation.
    Lai Q; Avolio AW; Manzia TM; Sorge R; Agnes S; Tisone G; Berloco PB; Rossi M
    Clin Transplant; 2012; 26(2):E125-31. PubMed ID: 22192083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time of hepatocellular carcinoma recurrence after liver resection and alpha-fetoprotein are important prognostic factors for salvage liver transplantation.
    Lee S; Hyuck David Kwon C; Man Kim J; Joh JW; Woon Paik S; Kim BW; Wang HJ; Lee KW; Suh KS; Lee SK
    Liver Transpl; 2014 Sep; 20(9):1057-63. PubMed ID: 24862741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma.
    Merani S; Majno P; Kneteman NM; Berney T; Morel P; Mentha G; Toso C
    J Hepatol; 2011 Oct; 55(4):814-9. PubMed ID: 21334400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor.
    Vitale A; Farinati F; Burra P; Trevisani F; Giannini EG; Ciccarese F; Piscaglia F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Cabibbo G; Felder M; Sacco R; Morisco F; Missale G; Foschi FG; Gasbarrini A; Svegliati Baroni G; Virdone R; Chiaramonte M; Spolverato G; Cillo U;
    Liver Transpl; 2015 Oct; 21(10):1250-8. PubMed ID: 26183802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients.
    Yang SH; Suh KS; Lee HW; Cho EH; Cho JY; Cho YB; Yi NJ; Lee KU
    Liver Transpl; 2006 Nov; 12(11):1655-60. PubMed ID: 16964589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-dimensional tumor volume and serum alpha-fetoprotein are predictors of hepatocellular carcinoma recurrence after liver transplantation: refined selection criteria.
    Kashkoush S; El Moghazy W; Kawahara T; Gala-Lopez B; Toso C; Kneteman NM
    Clin Transplant; 2014 Jun; 28(6):728-36. PubMed ID: 24708263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver transplantation for hepatocellular carcinoma: analysis of factors predicting outcome in 1074 patients in OPTN Region 5.
    Macdonald B; Sewell JL; Harper AM; Roberts JP; Yao FY
    Clin Transplant; 2015 Jun; 29(6):506-12. PubMed ID: 25777321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma.
    Yang SH; Suh KS; Lee HW; Cho EH; Cho JY; Cho YB; Kim IH; Yi NJ; Lee KU
    Surgery; 2007 May; 141(5):598-609. PubMed ID: 17462459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation.
    Cillo U; Giuliani T; Polacco M; Herrero Manley LM; Crivellari G; Vitale A
    World J Gastroenterol; 2016 Jan; 22(1):232-52. PubMed ID: 26755873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation.
    Hong G; Suh KS; Suh SW; Yoo T; Kim H; Park MS; Choi Y; Paeng JC; Yi NJ; Lee KW
    J Hepatol; 2016 Apr; 64(4):852-9. PubMed ID: 26658686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria.
    Hanouneh IA; Macaron C; Lopez R; Aucejo F; Zein NN
    Transplant Proc; 2011 Dec; 43(10):3813-8. PubMed ID: 22172852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying patients at higher risk of hepatocellular carcinoma recurrence after liver transplantation in a multicenter cohort study from Argentina.
    Piñero F; Marciano S; Anders M; Orozco Ganem F; Zerega A; Cagliani J; Andriani O; de Santibañes E; Gil O; Podestá LG; McCormack L; Gadano A; Silva M
    Eur J Gastroenterol Hepatol; 2016 Apr; 28(4):421-7. PubMed ID: 26684693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutrophil and platelet-to-lymphocyte ratio as new predictors of dropout and recurrence after liver transplantation for hepatocellular cancer.
    Lai Q; Castro Santa E; Rico Juri JM; Pinheiro RS; Lerut J
    Transpl Int; 2014 Jan; 27(1):32-41. PubMed ID: 24118272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.